Anatomic Lung Resection Is Associated With Improved Survival Compared With Wedge Resection for Stage IA (≤2 cm) NSCLC

IF 20.8 1区 医学 Q1 ONCOLOGY Journal of Thoracic Oncology Pub Date : 2025-08-01 Epub Date: 2025-03-23 DOI:10.1016/j.jtho.2025.03.042
Christopher W. Seder MD , Shu-Ching Chang PhD , Christopher W. Towe MD , Varun Puri MD , Justin D. Blasberg MD , Levi Bonnell PhD , Felix G. Fernandez MD , Robert H. Habib PhD , Benjamin D. Kozower MD, MPH
{"title":"Anatomic Lung Resection Is Associated With Improved Survival Compared With Wedge Resection for Stage IA (≤2 cm) NSCLC","authors":"Christopher W. Seder MD ,&nbsp;Shu-Ching Chang PhD ,&nbsp;Christopher W. Towe MD ,&nbsp;Varun Puri MD ,&nbsp;Justin D. Blasberg MD ,&nbsp;Levi Bonnell PhD ,&nbsp;Felix G. Fernandez MD ,&nbsp;Robert H. Habib PhD ,&nbsp;Benjamin D. Kozower MD, MPH","doi":"10.1016/j.jtho.2025.03.042","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>Given the uncertain generalizability of recent clinical trial data, a comparative effectiveness analysis evaluating the long-term survival of “real world” patients may clarify the role of lobectomy and sublobar resection (segmentectomy or wedge resection) in the treatment of early stage NSCLC.</div></div><div><h3>Methods</h3><div>Adult patients undergoing lung resection for clinical stage IA NSCLC (≤2 cm) between 2012 and 2022 were identified from the Society of Thoracic Surgeons General Thoracic Surgery Database. Long-term vital status was determined by linkage to the National Death Index and Centers for Medicare &amp; Medicaid Services inpatient data. The primary end point was overall survival (OS); secondary end points included lung cancer-specific survival (LCSS). Stabilized inverse probability weighted Cox regression was used to account for selection bias and derive hazard ratios (HRs) with 95% confidence intervals comparing the lobectomy, segmentectomy, and wedge resection cohorts.</div></div><div><h3>Results</h3><div>Overall, 32,340 patients with stage IA NSCLC (19,778 lobectomies [OS = 71.9% (5 y), 44.8% (10 y)], 4279 segmentectomies [OS = 69.6%, 44.2%], and 8283 wedge resections [OS = 66.3%, 41.4%]) were evaluated. After risk adjustment, lobectomy was associated with improved OS and LCSS compared with sublobar resection (HR [OS] = 0.87 [0.83–0.92]; HR [LCSS] = 0.84 [0.73–0.97]). Both lobectomy (HR [OS] = 0.84 [0.80–0.88]; HR [LCSS] = 0.72 [0.56–0.93]) and segmentectomy (HR [OS] = 0.88 [0.81–0.95]; HR [LCSS] = 0.77 [0.66–0.89]) were associated with improved survival compared with wedge resection. No differences in OS or LCSS were observed between lobectomy and segmentectomy.</div></div><div><h3>Conclusion</h3><div>In routine clinical practice, lobectomy and segmentectomy are associated with improved OS and LCSS compared with wedge resection for stage IA NSCLC (≤2 cm). These findings highlight the potential gap between trial efficacy and real-world effectiveness.</div></div>","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 8","pages":"Pages 1075-1085"},"PeriodicalIF":20.8000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Thoracic Oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1556086425006410","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/23 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction

Given the uncertain generalizability of recent clinical trial data, a comparative effectiveness analysis evaluating the long-term survival of “real world” patients may clarify the role of lobectomy and sublobar resection (segmentectomy or wedge resection) in the treatment of early stage NSCLC.

Methods

Adult patients undergoing lung resection for clinical stage IA NSCLC (≤2 cm) between 2012 and 2022 were identified from the Society of Thoracic Surgeons General Thoracic Surgery Database. Long-term vital status was determined by linkage to the National Death Index and Centers for Medicare & Medicaid Services inpatient data. The primary end point was overall survival (OS); secondary end points included lung cancer-specific survival (LCSS). Stabilized inverse probability weighted Cox regression was used to account for selection bias and derive hazard ratios (HRs) with 95% confidence intervals comparing the lobectomy, segmentectomy, and wedge resection cohorts.

Results

Overall, 32,340 patients with stage IA NSCLC (19,778 lobectomies [OS = 71.9% (5 y), 44.8% (10 y)], 4279 segmentectomies [OS = 69.6%, 44.2%], and 8283 wedge resections [OS = 66.3%, 41.4%]) were evaluated. After risk adjustment, lobectomy was associated with improved OS and LCSS compared with sublobar resection (HR [OS] = 0.87 [0.83–0.92]; HR [LCSS] = 0.84 [0.73–0.97]). Both lobectomy (HR [OS] = 0.84 [0.80–0.88]; HR [LCSS] = 0.72 [0.56–0.93]) and segmentectomy (HR [OS] = 0.88 [0.81–0.95]; HR [LCSS] = 0.77 [0.66–0.89]) were associated with improved survival compared with wedge resection. No differences in OS or LCSS were observed between lobectomy and segmentectomy.

Conclusion

In routine clinical practice, lobectomy and segmentectomy are associated with improved OS and LCSS compared with wedge resection for stage IA NSCLC (≤2 cm). These findings highlight the potential gap between trial efficacy and real-world effectiveness.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
对于IA期(≤2cm)非小细胞肺癌,解剖性肺切除术与楔形肺切除术相比可提高生存率。
导论:鉴于近期临床试验数据的不确定性,一项研究“现实世界”患者长期生存的比较有效性分析可能会阐明肺叶切除术和叶下切除术(节段切除术或楔形切除术)在治疗早期非小细胞肺癌(NSCLC)中的作用。方法:从2012年至2022年胸外科医师协会普通胸外科数据库中确定临床期IA期NSCLC(≤2 cm)行肺切除术的成年患者。通过与国家死亡指数和医疗保险和医疗补助服务中心住院患者数据的联系来确定长期生命状态。主要终点是总生存期(OS);次要终点包括肺癌特异性生存期(LCSS)。使用稳定的逆概率加权Cox回归来解释选择偏倚,并得出比较肺叶切除术、节段切除术和楔形切除术队列的95%置信区间的风险比(HR)。结果:总的来说,32340例IA期NSCLC患者(19,778例肺叶切除术[OS=71.9%(5年),44.8%(10年)],4,279例节段切除术[OS=69.6%, 44.2%], 8,283例楔形切除术[OS=66.3%, 41.4%])接受了检查。风险调整后,与叶下切除术相比,肺叶切除术与改善的OS和LCSS相关[HR(OS)=0.87(0.83-0.92);人力资源(lcs) = 0.84(0.73 - -0.97)]。双侧肺叶切除术[HR(OS)=0.84(0.80-0.88);人力资源(lcs) = 0.72(0.56 - -0.93)]和侧(人力资源(OS) = 0.88 (0.81 - -0.95);与楔形切除术相比,HR(LCSS)=0.77(0.66-0.89)与生存率提高相关。肺叶切除术和节段切除术在OS和LCSS方面没有差异。结论:在常规临床实践中,对于IA期(≤2 cm)的NSCLC,与楔形切除术相比,肺叶切除术和节段切除术可提高总体生存率和肺癌特异性生存率。这些发现突出了试验效果与实际效果之间的潜在差距。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Journal of Thoracic Oncology
Journal of Thoracic Oncology 医学-呼吸系统
CiteScore
36.00
自引率
3.90%
发文量
1406
审稿时长
13 days
期刊介绍: Journal of Thoracic Oncology (JTO), the official journal of the International Association for the Study of Lung Cancer,is the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies.The readship includes epidemiologists, medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, radiologists, pathologists, nuclear medicine physicians, and research scientists with a special interest in thoracic oncology.
期刊最新文献
Definitive Radiotherapy to the Primary Tumor in Stage IV NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer Advanced Radiation Technology Subcommittee. Targeting MET in EGFR-mutated NSCLC. Retinoblastoma Proficient Small Cell Carcinoma: A Novel Entity with Therapeutic Vulnerability? Masahiro Tsuboi, MD, PhD (1961-2026). ERBB2 activating mutations and co-occurring genomic alterations contribute to disease heterogeneity in patients with ERBB2-mutant lung cancer.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1